secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eiger BioPharmaceuticals, Inc. (—)
CIK:        0001305253
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003855
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eiger BioPharmaceuticals completes 1-for-30 reverse stock split effective Jan 5, 2024
--------------------------------------------------------------------------------

- Reverse stock split ratio of 1:30 approved by stockholders on Dec 28, 2023 and Board.
- Effective at 11:59 p.m. ET on Jan 5, 2024; stock began split-adjusted trading Jan 8, 2024.
- No fractional shares issued; cash paid in lieu based on Nasdaq closing price prior to effective date.
- New CUSIP number 28249U204 assigned to common stock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1305253/000119312524003855/0001193125-24-003855-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1305253/000119312524003855/d111539d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003855

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer